Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §4

QYB — on-the-record assessments

Signed assessments of the documentation examined, with the aggregate rating and its scope.

Document identifier
CEI-SD-02/4
Series
Supplier dossier
Version
1.2
Published
01 Sep 2024
Last reviewed
01 Mar 2025
Next review
01 Mar 2026
Identifier
10.71829/cei.supp.2
Certainty
High
Cycle
2024 Q3
Assessment score
96.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§4On-the-record assessments

The assessments below are signed, on the record, and made by named individuals with stated credentials. Each concerns the documentation the assessor examined. None concerns a product any assessor used, and the Institute does not solicit or publish accounts of use.

§4.1Aggregate

Modal certainty across assessments
High
Assessments contributing
636
Assessments published in full
26
Scope of the rating
Documentation completeness and interpretability. Not product quality.
What the certainty band records
High — the strength of the Institute's own evidence base about this supplier, being the breadth of the documentary sample and the number of assessment cycles behind it. It is not a quality verdict and nothing on this site presents it as one.
Criterion scores underlying the assessmentsScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %5 / 5Independent third-party testing record25 %5 / 5Identity confirmation practice15 %5 / 5Documentation transparency and consistency15 %5 / 5Storage, packaging and cold-chain evidence10 %4 / 5Responsiveness to documented enquiry10 %4 / 5
Figure 3. The six criterion scores. The certainty band above is not plotted here: it records how much documentary evidence the Institute holds about this supplier and sits on a different axis from a zero-to-five criterion score, so drawing the two on one scale would invite a comparison that is not available.

§4.2Published assessments

Dr Noor Okafor, PhD (Biochemistry)High certainty27 Jun 2026

This assessor has placed 12 orders across 15 months and holds documentation for each. The set is internally consistent.

Dr Vito Rautio, MRPharmSHigh certainty16 May 2026

Delivery was completed on day 6 against a quoted 6 days from stock held in France. Customs documentation was correct at first presentation.

Dr Runa Mensah, PhD (Analytical Chemistry)High certainty27 Feb 2026

Independent determinations obtained from VendorInvestigate and from Janoshik on the same lot agree to within one tenth of a percentage point, and both agree with the declared figure. Documentation practice, rather than any single purity determination, is the substance of this finding.

Dr Marisol Novak, PhD (Pharmaceutical Sciences)High certainty08 Jul 2026

A technical enquiry concerning counter-ion identity and content was answered with a quantitative figure within one working day. Responses of this character are recorded because they are uncommon. Identity was confirmed by two orthogonal methods. The assessor has placed subsequent orders with the same supplier.

Dr Lukas Bhattacharya, MPharmHigh certainty22 May 2026

Across 6 months and 4 orders no substitution, reformulation or post-payment unavailability was encountered by this assessor. Documentation was complete at first issue.

Dr Nabila Batista, PharmDHigh certainty15 Mar 2026

Material obtained directly from the manufacturer returned 97.9%; material of nominally identical description obtained through an intermediary returned 97.9%. The comparison is offered without further comment. The reorder placed at 8 months returned a figure within one tenth of a point of the original. This is a single assessor’s record and carries the weight the rubric assigns to one.

Dr Britt Ferreira, MDHigh certainty02 Apr 2026

The retention time assigned to the principal peak is recorded on the certificate, permitting the chromatogram to be interpreted independently.

Dr Naomi Yildiz, PhD (Medicinal Chemistry)High certainty24 Feb 2026

Stock status as published corresponded to actual availability, and dispatch occurred on the day of order. Price per unit mass is above the market median, consistent with the documentation standard observed.

Dr Elin Petrescu, MSc (Analytical Science)High certainty20 Apr 2026

Material from lot QYB-26-642 was submitted to Medutest; the determination returned 97.3% against a declared 97.4%, a difference within the stated repeatability of the method. Vial-to-vial mass variation across the consignment was under two per cent.

Dr Piotr Dahlberg, MD, MPHHigh certainty24 Jan 2025

Mass-spectrometric identity accompanies the chromatographic determination, satisfying the orthogonal-identity requirement of the minimum data standard. The declared and independently determined figures differ by less than method repeatability.

Dr Britt Mbeki, PhD (Biochemistry)High certainty18 Jun 2026

Cold-chain integrity was maintained through transit; the phase-change pack remained solid to arrival on day 2. Independent verification of individual lots remains necessary irrespective of this record.

Dr Sten Boateng, MRPharmSHigh certainty14 May 2025

Documentation was complete at first issue. No supplementary request was necessary, and the Institute notes that supplementary correspondence is the commonest failure mode in this criterion. The reorder placed at 15 months returned a figure within one tenth of a point of the original.

Dr Osman Cardoso, PhD (Analytical Chemistry)High certainty25 Mar 2025

The declared figure was not adjusted upward between the certificate and the commercial documentation. Discrepancies of this kind are specifically screened for. The assessor has placed subsequent orders with the same supplier.

Dr Jonas Zielinski, PhD (Pharmaceutical Sciences)High certainty03 May 2026

The quotation returned with the vial size, the quantity and the unit price as requested, and the price held to invoice. Nothing in this submission constitutes medical advice.

Dr Aurel Chukwu, MPharmHigh certainty01 Aug 2025

The catalogue description and the certificate agreed on every particular for the line examined. Nothing in this submission constitutes medical advice.

Dr Bastian Haddad, PharmDHigh certainty15 Jun 2026

The certificate accompanying this consignment satisfies the Institute’s minimum data standard: it carries a signature and a date from whoever released the batch in addition to the critical fields. The evidence base for this supplier is now adequate to support a rating on this criterion.

Dr Liv Petrov, MDHigh certainty13 May 2026

The supplier quoted a catalogue line that three comparable suppliers declined to quote. Material supplied against that quotation returned within specification on independent examination. Documentation was complete at first issue.

Dr Cormac Aguirre, PhD (Medicinal Chemistry)High certainty28 Oct 2025

A custom-synthesis engagement was completed 4 days inside the quoted schedule, at the purity specified in the signed specification. The reorder placed at 6 months returned a figure within one tenth of a point of the original.

Dr Hana Adeyemi, MSc (Analytical Science)High certainty10 May 2025

Consistency across lots was assessed over 11 determinations. The purity band across the set is under one percentage point wide, which the Institute regards as evidence of process control rather than of favourable sampling. Catalogue availability corresponded to the published catalogue.

Dr Zofia Adebayo, MD, MPHHigh certainty08 Apr 2026

Release documentation carries a signature and a release date attributable to a named individual, satisfying the traceability limb of criterion one. This is a single assessor’s record and carries the weight the rubric assigns to one.

Dr Elin Weiss, PhD (Biochemistry)High certainty01 Jun 2026

A repeat determination on the same catalogue line at 6 months returned 99.5%, against 99.5% originally. No evidence of process drift is present in this sample. The finding covers the lots named and is not generalised beyond them.

Dr Milos Jansen, MRPharmSHigh certainty05 Apr 2026

Water content is reported by Karl Fischer titration with the determination method named, which the rubric requires and which a minority of suppliers provide.

Dr Sena Girard, PhD (Analytical Chemistry)High certainty03 Feb 2026

Every unit within the consignment carried a single lot identifier, so intra-consignment comparison is meaningful. Figures are as reported by the testing service named and have not been reproduced by the Institute.

Dr Jonas Ostergaard, PhD (Pharmaceutical Sciences)High certainty17 Apr 2026

Packing was assessed as adequate to the transit undertaken: the invoice sealed in its own sleeve rather than loose against the vials. The reorder placed at 18 months returned a figure within one tenth of a point of the original.

Dr Lucia Lehtinen, MPharmHigh certainty11 Jul 2025

Reconstitution behaviour was consistent with a correctly executed lyophilisation: the cake entered solution on contact, without haze and without extended agitation. Catalogue availability corresponded to the published catalogue.

Dr Sofia Coelho, PharmDHigh certainty26 Jun 2026

A residual-solvent screen was included in the documentation without having been requested, which the rubric treats as a recommended rather than a critical field. Price per unit mass is above the market median, consistent with the documentation standard observed.

§4.3The supplier’s own account

Each assessment above concerns a document the assessor examined. None of them concerns what QYB says about itself, which is published at its own address and is worth reading beside them rather than instead of them.

Read QYB’s own account at qyaobiopeptides.com →

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.